Key Points
LLY expects $6.85 EPS and $17.6B revenue on April 30
Company beat estimates in 3 of last 4 quarters
Stock trades at premium 38x P/E with limited downside room
Analyst consensus overwhelmingly bullish with 39 Buy ratings
Eli Lilly and Company (LLY) reports earnings on April 30, 2026, with analysts expecting $6.85 EPS and $17.6 billion in revenue. The pharmaceutical giant has beaten earnings estimates in three of its last four quarters, showing strong momentum in its diabetes and oncology portfolios. With a market cap of $826 billion and a B+ grade from Meyka AI, LLY remains a heavyweight in healthcare. Investors will focus on GLP-1 drug performance, international expansion, and pipeline progress. The stock trades at $874, up 0.66% today, as the market awaits this critical earnings release.
Earnings Estimates and Historical Performance
Analysts project $6.85 EPS and $17.6 billion revenue for this quarter. This represents a modest decline from the previous quarter’s $7.54 EPS but aligns with LLY’s strong earnings trajectory.
Recent Beat Pattern
Lilly has exceeded EPS expectations in three of the last four quarters. In February 2026, the company delivered $7.54 EPS against a $6.91 estimate, beating by 9.1%. Revenue came in at $19.3 billion versus $17.9 billion expected, a 7.5% beat. This consistent outperformance suggests management’s ability to drive operational efficiency and revenue growth.
Revenue Momentum
Lilly’s revenue has grown substantially year-over-year. The most recent quarter showed $19.3 billion, up from $17.6 billion in the prior year period. This 9.7% growth reflects strong demand for Trulicity, Jardiance, and newer oncology drugs. The current $17.6 billion estimate appears conservative given recent performance trends.
EPS Trajectory
Earnings per share have improved significantly. The company posted $7.54 EPS in February, $7.02 EPS in October, and $6.31 EPS in August. The current $6.85 estimate sits between recent quarters, suggesting stabilization after strong prior results.
What Investors Should Watch
Several key metrics will determine whether LLY beats or misses expectations this quarter.
GLP-1 Drug Sales
Tirzepatide sales momentum remains critical. Lilly’s GLP-1 franchise competes directly with Novo Nordisk’s Ozempic. Investors want to see accelerating adoption, international expansion, and pricing power. Any slowdown in this segment could pressure the stock significantly.
Oncology Portfolio Performance
Drugs like Verzenio, Retevmo, and Cyramza drive growth. These cancer treatments address large markets with limited competition. Strong oncology sales would support the $6.85 EPS estimate and justify the stock’s premium valuation.
International Revenue
Lilly generates roughly 50% of revenue internationally. Currency headwinds and regulatory approvals in Europe and Asia matter. Management guidance on emerging market expansion will influence forward estimates.
R&D Spending and Pipeline
Investors monitor R&D efficiency and pipeline progress. Lilly invests heavily in Alzheimer’s disease treatments and immunology. Updates on clinical trials and regulatory submissions could shift long-term growth expectations.
Valuation and Market Context
LLY trades at a 38.05 P/E ratio, significantly above the S&P 500 average of 20-22. This premium reflects investor confidence in growth prospects.
Price-to-Sales Analysis
The stock trades at 12.66x sales, indicating high expectations are priced in. For context, the healthcare sector average is 4-6x. This valuation leaves limited room for disappointment. A miss on revenue or guidance could trigger a sharp pullback.
Debt and Financial Health
Lilly maintains a 1.60 debt-to-equity ratio and strong interest coverage of 37.3x. The company generates $18.7 billion in operating cash flow annually. This financial strength supports R&D investment and shareholder returns, including a 0.71% dividend yield.
Technical Setup
The stock recently pulled back from its $1,133.95 year high, now trading near support. RSI sits at 37.15, suggesting oversold conditions. A positive earnings surprise could spark a recovery toward recent highs.
Meyka AI Grade and Analyst Consensus
Meyka AI rates LLY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Analyst Sentiment
Wall Street consensus is overwhelmingly bullish. 39 analysts rate LLY as Buy, while only 4 rate it Hold. No analysts recommend selling. This unanimous support reflects confidence in the company’s competitive moat and growth runway.
Beat Probability
Based on historical performance, LLY has a strong track record of beating estimates. Three of four recent quarters exceeded expectations. The current $6.85 EPS estimate appears achievable given recent results. However, revenue estimates at $17.6 billion may be conservative relative to recent quarters’ $19.3 billion performance.
Forecast Outlook
Meyka’s price forecasts suggest upside potential. The yearly forecast stands at $1,152.87, implying 32% upside from current levels. The five-year forecast of $1,855.21 reflects confidence in long-term growth. These projections assume continued execution on earnings growth and market share gains.
Final Thoughts
Eli Lilly enters earnings with strong momentum and high expectations. The $6.85 EPS and $17.6 billion revenue estimates appear achievable based on recent beat patterns and operational performance. Investors should focus on GLP-1 sales trends, oncology portfolio strength, and management guidance on 2026 growth. The stock’s premium valuation at 38x P/E leaves limited room for error, but LLY’s consistent execution and robust pipeline support the bull case. A beat on both metrics could drive the stock toward $1,100+, while a miss could trigger a 5-10% pullback. The B+ Meyka grade reflects balanced risk-reward at current levels.
FAQs
What are the earnings estimates for LLY on April 30?
Analysts expect **$6.85 EPS** and **$17.6 billion in revenue**. These estimates represent modest declines from the prior quarter but align with LLY’s strong historical performance and growth trajectory in diabetes and oncology markets.
Has Eli Lilly beaten earnings estimates recently?
Yes. LLY beat EPS estimates in three of the last four quarters. Most recently, the company delivered **$7.54 EPS** versus **$6.91 expected** in February 2026, a **9.1% beat**. Revenue also exceeded expectations by **7.5%**.
What should investors watch during the earnings call?
Monitor GLP-1 drug sales momentum, oncology portfolio performance, international revenue trends, and management guidance on 2026 growth. Updates on R&D pipeline progress and clinical trial results will influence long-term stock direction significantly.
What is the Meyka AI grade for LLY?
Meyka AI rates LLY with a **B+ grade**. This reflects S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade suggests balanced risk-reward at current valuation levels.
Will LLY beat or miss earnings estimates?
Based on historical beat patterns, LLY likely beats EPS estimates. However, revenue estimates at **$17.6 billion** appear conservative versus recent quarters’ **$19.3 billion**. A beat on both metrics is probable given recent operational momentum.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)